Healthcare professionals / Gastroenterology / HabibTM EndoHPB Bipolar Radiofrequency Catheter / Cholangiocarcinoma
  

Cholangiocarcinoma (Cca)

Clinical Challenge
  • Mean survivalis 6-121 months for the 60% of pts who arenon-surgical candidates
  • Mean stentpatency(plastic/metal): 3.4 / 8.4mo.2,3
  • Therefore, more than half of the patients may outlive thepatency of their stents
  • Patients typically experience biliary obstruction, which leads tocholangitis and liver failure, with is also a cause of death3.

Clinical Goal

Proactively manage patients with RFA to prolong patency

Literature Highlights

Data is for Ablation + stenting vs stenting alone

  • Average Patency Improvement:
    • Plastic 3.4 vs. 6.8 mo(p=0.02) 2
    • Metal 8.4 vs. 9.5mo (p=0.024) 3
  • Complication rates show no significant difference 6.36% vs. 9.1% p=0.672
  1. Sharaiha, R et al, Comparison of Metal Stenting with Radiofrequency Ablation Versus Stenting Alone for Treating Malignant Biliary Strictures: Is There an Added Benefit?, Dig Dis Sci, June 2014
  2. Yang, Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial,  Endoscopy 2018
  3. Liang et al., metal Stenting with or w/o Endobiliary RFA for Unresectable Extrahepatic Cholangiocarcinoma, Journal of Cancer Therapy, 2015, 6, 981-982
Top